Until only five years ago, Yuhan was the No. 1 pharmaceutical company in Korea, but it was criticized for being a company that sells foreign drugs and only acts as a wholesaler.

The company had very few pipelines. However, since President Lee Jung-hee took office in 2015, Yuhan's new drug pipeline has increased to 29 as of the end of last year. The sales share of R&D expenses also increased from 5.7% to 10.8%. This year, Yuhan plans to invest more than ₩130 billion in R&D.

Yuhan's Leclaza (Lazertinib mesylate) received conditional marketing authorization on the 18th. Leclaza's rival drug is Tagrisso (Osimertinib), which generates about ₩4 trillion in sales globally. Considerin